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Background:We investigated six London care homes experiencing a COVID-19 outbreak and found high rates
of SARS-CoV-2 infection among residents and staff. Here we report follow-up investigations including anti-
body testing in the same care homes five weeks later.
Methods: Residents and staff in the initial investigation had a repeat nasal swab for SARS-CoV-2 RT-PCR and a
blood test for SARS CoV-2 antibodies using ELISA based on SARS-CoV-2 native viral antigens derived from
infected cells and virus neutralisation.
Findings: Of the 518 residents and staff in the initial investigation, 186/241 (77.2%) surviving residents and 208/
254 (81.9%) staff underwent serological testing. Almost all SARS-CoV-2 RT-PCR positive residents and staff were
seropositive five weeks later, whether symptomatic (residents 35/35, 100%; staff, 22/22, 100%) or asymptom-
atic (residents 32/33, 97.0%; staff 21/22, 95.5%). Symptomatic but SARS-CoV-2 RT-PCR negative residents and
staff also had high seropositivity rates (residents 23/27, 85.2%; staff 18/21, 85.7%), as did asymptomatic RT-PCR
negative individuals (residents 61/91, 67.0%; staff 95/143, 66.4%). Neutralising antibody was detected in 118/
132 (89.4%) seropositive individuals and was not associated with age or symptoms. Ten residents (10/79 re-
tested, 12.7%) remained RT-PCR positive but with higher RT-PCR cycle threshold values; 7/10 had serological
testing and all were seropositive. New infections were detected in three residents and one staff.
Interpretation: RT-PCR provides a point prevalence of SARS-CoV-2 infection but significantly underestimates
total exposure in outbreak settings. In care homes experiencing large COVID-19 outbreaks, most residents
and staff had neutralising SARS-CoV-2 antibodies, which was not associated with age or symptoms.
Funding: PHE
Crown Copyright © 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)termeasures Division, Public
UK.
mez@aol.com (S.N. Ladhani).
er Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Introduction
Nursing and residential homes have been disproportionally
affected by COVID-19 with high rates of hospitalisations and deathsamong residents [1]. In England, the first cases of imported COVID-19
were confirmed in late January 2020 with autochthonous transmis-
sion established by early March 2020. Cases peaked in mid-April
before declining as a consequence of intense control measures [2].
London, England, was one of the most affected cities and large out-
breaks associated with high case fatality rates (CFR) among residents
were reported in London care homes [2].
Research in Context
Evidence before this study
We searched PubMed with the terms “COVID-19 outbreak” or
“SARS-CoV-2 outbreak” and “care home”, “nursing home”,
“nursing facility” or “residential home” to identify publications
relating to COVID-19 outbreaks since January 2020, focusing
particularly on enhanced outbreak investigations and antibody
testing. Outbreak investigations of single care homes have iden-
tified high rates of asymptomatic and pre-symptomatic SARS-
CoV-2 infection among residents and staff. There are very lim-
ited data on antibody responses to SARS-CoV-2 or the quality of
the antibodies in older people.
Added value of this study
In six London care homes experiencing a large outbreak of
COVID-19, 95100% of staff and surviving residents who had
initially tested positive for SARS-CoV-2 RT-PCR RNA on nasal
swab had detectable SARS-CoV-2 antibodies five weeks later.
Overall, more than two-thirds of residents and staff members
had detectable antibodies against SARS-CoV-2 irrespective of
their nasal swab results or symptom status. Neutralising anti-
bodies were present in 89% of seropositive individuals and
were not associated with age, sex, initial nasal swab positivity,
presence of symptoms or resident/staff status.
Implications of all the available evidence
RT-PCR testing for SARS-CoV-2 significantly underestimates the
true extent of an outbreak in institutional settings. SARS-CoV-2
seropositivity rates in the care homes affected by COVID-19
were far higher than any healthcare setting, including hospitals,
possibly because of the intensity and duration of exposure to
the virus within the care home setting. Surveillance is on-going
to determine whether SARS-CoV-2 antibodies protect against
re-infection and, if so, the duration of protection.
2 S.N. Ladhani et al. / EClinicalMedicine 28 (2020) 100597Between 1013 April 2020, we investigated six London care homes
reporting a suspected or confirmed COVID-19 outbreak to Public
Health England (PHE) [3]. We found that 40% of residents (105/264)
and 21% of staff (53/254) had confirmed SARS-CoV-2, with half of both
groups remaining asymptomatic throughout the surveillance period
[3]. Mass serological testing can help uncover the true extent of an out-
break within the care home setting, [4] and potentially inform staff
allocation and cohorting practices. Neutralising antibodies, in addition,
may provide evidence for protection against reinfection, especially
among the older residents who may not reliably mount an adequate
protective response despite antibody production because of immuno-
senescence [5,6]. As part of follow-up investigations, the residents and
staff in the six care homes experiencing a COVID-19 outbreak were fol-
lowed-up with a repeat nasal swab and a blood sample five weeks
after the initial investigations. The study aimed to estimate SARS-CoV-
2 seropositivity and neutralising antibodies in care home residents
and staff of care homes experiencing a COVID-19 outbreak and assess
any association with age, symptoms and SARS-CoV-2 reverse tran-
scription polymerase chain reaction (RT-PCR) positivity.
Methods
We identified six care homes reporting a suspected outbreak (2
suspected cases) of COVID-19 to PHE during 1013 April 2020 [3].
These were nursing or mixed nursing/residential homes of different
sizes, providing care for 43100 residents with 14130 staff. The
care homes were in different stages of a COVID-19 outbreak. Duringthe initial investigation, nasal swabs were taken for SARS-CoV-2 RT-
PCR for all residents and staff working in the care home at the time.
Infection control measures were reinforced and all SARS-CoV-2 RT-
PCR positive individuals were isolated. All tested participants were
followed up for any symptoms during the two weeks before, at the
time of testing and for two weeks after the test [3].
Follow-up investigation involved a repeat nasal swab and a blood
sample from all participants five weeks after the initial RT-PCR test-
ing. The follow-up investigation protocol was reviewed and approved
by PHE Research Ethics and Governance Group and participating care
homes. Care home managers obtained verbal consent from staff
members and from residents who could give their own consent. Oth-
erwise, their next of kin was contacted with information about the
additional testing and asked to provide verbal consent over the
phone. Testing began on the week of May 18, 2020. Care home staff
took nasal swabs for residents and submitted their own samples by
self-swabbing with appropriate instructions. Care home nurses took
blood samples from residents and their colleagues, with external
phlebotomists assisting two care homes with sampling.
SARS-CoV-2 antibody testing
SARS-CoV-2 infected virus lysate assay: Native virus antigen ELISA
was modified from a previously described MERS-CoV assay [7,8].
Microplate bound detergent (Triton X100) extracted lysates of SARS-
CoV-2 (isolate England/02/2020) infected Vero E6 cells and unin-
fected cells were reacted with a serial dilution of convalescent serum
obtained from participants in an indirect ELISA format. Virus lysates
contained a mixture of viral proteins expressed in Vero E6 cells,
including viral nucleocapsid and spike proteins. The reactivity of
given sera against virus infected cells and uninfected cells is com-
pared creating a single index value. Sensitivity was determined using
convalescent serum samples from SARS-CoV-2 RT-PCR positive indi-
viduals at least 21 days after the positive respiratory tract swab [9].
Microneutralisation assay and neutralising antibody titre
SARS-CoV-2 (isolate England/02/2020) specific neutralising anti-
body levels were measured using a modification of the WHO influ-
enza microneutralisation methodology [10]. Briefly, 200 TCID 50 of
virus was incubated with serial dilutions of serum from participants,
after which a suspension of Vero E6 cells were added. After 22 h, cells
were fixed and in-cell SARS-CoV-2 nucleoprotein (NP) expression
determined by ELISA using Rabbit polyclonal to SARS-CoV Nucleopro-
tein (SinoBiological; Cat no 40143-T62).
The virus neutralising antibody titre was determined as the serum
concentration that inhibited 50% SARS-CoV-2 NP expression. All work
was undertaken in a BSL-3 laboratory.
SARS-CoV-2 PCR
Nucleic acid was extracted from samples and analysed by a real-
time RT-PCR assay targeting a conserved region of the open reading
frame 1ab (ORF1ab) gene of SARS-CoV-2, together with detection of
an assay internal control to monitor the extraction and RT-PCR pro-
cesses. This assay used the primers and probe sequences made public
by CDC China (http://ivdc.chinacdc.cn/kyjz/202001/t20200121_
211337.html) and required 5mL RNA in a total RT-PCR reaction vol-
ume of 25mL. Reverse transcription and PCR amplification was per-
formed on an Applied Biosystems 7500 FAST system.
Statistical analysis
Descriptive analyses were performed. Data that did not follow a
normal distribution were described as medians with interquartile
ranges and compared using the Mann-Whitney U test. Antibody
Fig. 1. Flow diagram of residents and staff in 6 London care homes experiencing a COVID-19 outbreak during the pandemic who consented to follow-up testing including blood
sampling for SARS-CoV-2 antibodies four to six weeks later. ‘Ever-symptomatic’ indicates that symptoms were experienced at some point during the follow-up period.
*Three individuals in this group became SARS-CoV-2 PCR positive at follow-up RT-PCR testing conducted simultaneously with SARS-CoV-2 antibody testing.
S.N. Ladhani et al. / EClinicalMedicine 28 (2020) 100597 3concentrations were presented as ELISA index values with medians
and 95% confidence intervals (95% CI). Antibody concentrations above
the index value of 0.5 were considered positive. Median antibody
concentrations were compared using Kruskal-Wallis with Dunn’s
multiple comparisons test adjustment. Categorical variables were
described as proportions and compared using Chi -square or Fisher’s
Exact test as appropriate. Data were analysed using Stata version
15.0 (Statcorp, Tx) and GraphPad Prism.
Ethics approval: The research protocol was approved by the PHE
Research Ethics and Governance Group (REGG Ref: NR0204, 07 May
2020).
Role of the funding source: This study was funded by Public
Health England as part of the COVID-19 response. The authors had
sole responsibility for the study design, data collection, data analysis,
data interpretation, and writing of the report. The authors are all
employed by Public Health England, the study funder, which is a pub-
lic body — an executive agency of the Department of Health. SNL and
MZ had full access to all the data in the study and final responsibility
for the decision to submit for publication.
Results
Seropositivity
Of the original 518 residents and staff involved in the initial care
home outbreak investigation during 1013 April 2020, 394 (76.1%)
consented for follow-up investigations at median of 36 days (range,
3045 days) and were tested using the virus lysate antibody assay
(Fig. 1). SARS-CoV-2 seropositivity for the cohort was 77.9% (95%CI,
73.681.7%; Table 1, Fig. 2a). Seropositivity was associated with
being symptomatic and SARS-CoV-2 RT-PCR nasal swab positive at
the initial test (Fisher’s exact test; both p<0.0001), but not with gen-
der or being a resident or staff member (Table 1, Fig. 2).
Residents
Twenty-one of the 264 residents tested in the initial investigations
died within two weeks and two others died prior to follow-up testing.Thus, 186 of the remaining 241 residents consented to SARS-CoV-2
antibody testing and 81.2% (151/186) were seropositive. Of the 186
residents for who convalescent serological analysis was available 35
had been symptomatic and RT-PCR positive during the initial testing
period; all were SARS-CoV-2 antibody positive (Fig. 1, Fig. 2c). For the
residents who were RT-PCR positive but remained asymptomatic
throughout the outbreak, 97.0% (32/33) were SARS-CoV-2 antibody
positive (Fig. 1, Fig. 2c). Of the 118 residents with convalescent serol-
ogy who had tested RT-PCR negative initially, seropositivity was 85.2%
(23/27) in those who had been symptomatic during the outbreak and
67.0% (61/91) in residents who remained asymptomatic (Fig. 1, Fig. 2c).
Staff
Among the 254 staff members involved in the initial investigation,
208 consented to additional investigations and 75.0% (156/208) were
seropositive (Fig. 2a). All of those who were SARS-CoV-2 RT-PCR posi-
tive at initial testing and symptomatic during the outbreak were posi-
tive for SARS-CoV-2 antibodies (22/22), as were 95.5% (21/22) of RT-
PCR positive asymptomatic staff (Fig. 1, Fig. 2c). Of the 164 staff mem-
bers with convalescent serology who were SARS-CoV-2 RT-PCR nega-
tive at the initial test time point 21 experienced COVID-19
compatible symptoms during the follow-up period and 18 (85.7%)
were SARS-CoV-2 antibody positive. The remaining 143 SARS-CoV-2
PCR negative staff undergoing serological analysis remained asymp-
tomatic throughout the surveillance period; 95 (66.4%) were SARS-
CoV-2 antibody positive (Fig. 1, Fig. 2c).
SARS-CoV-2 antibody seropositivity and index values
There was no association between SARS-CoV-2 seropositivity and
age (Chi-square test, P = 0.43, Table 1) (Fig. 3, left panel). Among
SARS-CoV-2 antibody positive individuals, there was no significant
difference in median index value between the those who had been
PCR positive or negative at initial testing (Mann-Whitney U Test
P = 0.05; Supplementary figure 1a) or by age (Kruskal Wallis with
Dunn’s multiple comparisons test P = 0.07; Fig. 3, right panel). There
was no association between median SARS-CoV-2 antibody index
Table 1
Demographics of care homes cohort and seropositivity by group: percentage and 95%
confidence intervals shown. Statistical analysis using Fisher's exact test(f) and Chi-
square test of proportions(c), p values as shown.
n % total Seropositive (n) (%) 95% CI
Overall 394 100 307 77.9 73.6 - 81.7
Sex
Male 95 24.1 73 76.8 67.4 - 84.2
Female 299 75.9 234 78.3 73.2 - 82.6
p value(f) 0.78
Age group
1939 66 16.8 49 74.2 62.6  83.3
4059 113 28.7 88 77.9 69.4  84.5
6079 71 18.0 52 73.2 61.9  82.1
>80 144 36.5 118 81.9 74.9  87.4
p value(c) 0.43
Residents and Staff
Residents 186 47.2 151 81.2 75.0 - 86.1
Staff 208 52.8 156 75.0 68.7 - 80.4
p value(f) 0.15
Symptoms at any time during first test period
Symptomatic 105 26.6 98 93.3 86.9 - 96.7
Asymptomatic 289 73.4 209 72.3 66.9 - 77.2
p value(f) <0.0001
First round PCR results
1st PCR + 112 28.4 110 98.2 93.7 - 99.7
1st PCR - 282 71.6 197 69.9 64.3 - 74.9
p value(f) <0.0001
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mentary figure 1b), or gender (Mann-Whitney U Test P = 0.57; Sup-
plementary figure 1c). Six individuals had equivocal SARS-CoV-2
antibody index values; all were asymptomatic throughout the sur-
veillance period and were SARS-CoV-2 RT-PCR negative on nasal
swabs at both timepoints.
Neutralising antibodies
Neutralising antibodies were detected in 89.4% (118/132) of sero-
positive individuals. There was no association between the detection
of SARS-CoV-2 neutralising antibodies and age (Chi-square test
P = 0.27; Fig. 4a) or PCR status (Fisher’s exact test P = 0.77); data not
shown. There was no significant difference in neutralising antibody
titre by sex (Mann-Whitney U test P = 0.69; Fig. 4b), or symptom sta-
tus (Mann-Whitney U test P = 0.10; Fig. 4c). There was a trend toward
increasing neutralising antibody titre with age (Kruskal-Wallis test
with Dunn’s Multiple comparisons, P = 0.40; Fig. 4d).Fig. 2. Proportion of indicated study populations with positive (maroon), equivocal (yellow)
staff and resident sub groups. b) Seroconversion by sex for whole cohort. c) Seroconversion
Staff N = 208; Residents N = 186.Nasal swab RT-PCR
All consenting residents and staff had a repeat nasal swab at the
time of convalescent blood sampling. Thirteen residents were SARS-
CoV-2 RT-PCR positive on this repeat sample, including 10 who had
been SARS-CoV-2 RT-PCR positive at an interval of 3645 days previ-
ously, although SARS-CoV-2 RT-PCR Ct values were significantly
lower at follow-up (Supplementary Figure 2). Of these ten, 7 con-
sented to serum sampling and all were seropositive with neutralising
antibodies detected in all of those tested (Supplementary Table 1).
Three residents became SARS-CoV-2 RT-PCR positive at follow-up
and all were seropositive (Fig. 1); all remained asymptomatic. None
of the staff who were SARS-CoV-2 RT-PCR positive at the initial visit
were positive on repeat testing. A previously SARS-CoV-2 RT-PCR
negative staff member who remained asymptomatic throughout the
surveillance period became RT-PCR positive on repeat testing, with a
Ct value of 35.6; this staff member was seropositive for SARS-CoV-2
antibodies.or negative (green) native viral antigen lysate assay. a) Seroconversion for all cohort and
by acute RT-PCR result and presence of symptoms for residents and staff. All N = 394;
Fig. 3. Age group analysis native viral antigen lysate assay. Left panel: Seroconversion percentage by age group for whole cohort, N = 394. Right panel: Native viral antigen assay
index value for seropositive individuals by initial RT-PCR status and age group, N = 307. Bars indicate median and 95% confidence interval. Dashed line indicates assay positive cut-
off. Statistical analysis using Chi-square test of proportion (p = 0.43) and Kruskal-Wallis with Dunn’s multiple comparisons test (p = 0.07).
Fig. 4. Virus neutralising antibody titre analysis. a) Virus neutralising antibody titre positive and negative percentage by age group for whole cohort. N = 132 b) Virus neutralisation
titre by sex. Bars indicate median and 95% confidence interval. c) Virus neutralisation titre by symptom status during the initial testing period. Bars indicate median and 95% confi-
dence interval. d) Virus neutralisation titre by age group. Box and whisker plot with bars indicating full range of results. N = 118. Statistical analysis a) Chi-square test, P = 0.27; b
Mann-Whitney U Test, P = 0.69; c) Mann-Whitney U Test, P = 0.10 d) Kruskal Wallis with Dunn’s multiple comparisons test adjustment, P = 0.40.
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In six London care homes experiencing a COVID-19 outbreak at
the peak of the pandemic, 81.2% of surviving residents and 75.0% of
staff were SARS-CoV-2 antibody positive five weeks after the initial
outbreak investigation. These rates are far higher than those reported
from any other cohort including frontline healthcare workers manag-
ing patients with confirmed COVID-19 in hospitals [1113]. Almost
all residents and staff who were SARS-CoV-2 RT-PCR positive on nasal
swab at initial testing developed SARS-CoV-2 antibodies, irrespective
of whether they were symptomatic at any point during the outbreak.
High seropositivity rates were also observed for symptomatic resi-
dents and staff even if they had a previously negative SARS-CoV-2
RT-PCR test. The serological investigation emphasises the extent to
which SARS-CoV-2 can penetrate vulnerable communities in closed
settings, and the underestimation of exposure through point preva-
lence estimates using RT-PCR from nasal swabs. The lowest seroprev-
alence was observed in residents and staff who remained
asymptomatic throughout the outbreak and who were SARS-CoV-2
RT-PCR negative on both testing visits but, even in this group, more
than two-thirds were positive for SARS-CoV-2 antibodies. In thiscohort, SARS-CoV-2 antibody levels were not associated with age,
sex, presence of symptoms, PCR-positivity or resident/staff status.
There are now sensitive and specific serological assays, such as the
one used in this investigation based on using native viral antigens
derived from infected cells [9]. Overall, a recent systematic review
estimated that serological tests had 30% sensitivity for SARS-CoV-2
antibodies during the first week after symptom onset, rising to 72%
in the second week, 91% in the third week and 96% up to 5 weeks
later [14]. The finding that almost all residents and staff with con-
firmed COVID-19 through nasal swab SARS-CoV-2 RT-PCR  irrespec-
tive of whether they ever experienced symptoms during the outbreak
 is reassuring and validates the use of our serological assay as a
measure of past exposure. The very high seropositivity rates among
symptomatic but RT-PCR negative residents and staff suggests that
their original illness was also most likely due to COVID-19 and high-
lights the sensitivity limitations of single point nasal swabbing for
diagnosis and the narrow window of SARS-CoV-2 detection in
infected individuals. RT-PCR significantly underestimated exposure
to SARS-CoV-2 in these outbreak settings [15]. The very high seropos-
itivity of 75.0% among care home staff compared to 1744% of
patient-facing healthcare workers is staggering [11,12]. A possible
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virus because of level of care required by the residents [15,16]. In our
initial investigations we also found evidence of transmission between
staff members in care homes, highlighting the importance of main-
taining infection control practices for all contact, including those
between staff, whilst on care home premises [8]. Despite reinforce-
ment of infection control measures at the outset, one further staff
member and three residents became infected with SARS-CoV-2 at fol-
low-up. Residents and staff who were SARS-CoV-2 RT-PCR positive at
follow-up all had high Ct values, consistent with non-viable virus at
the time of testing, [3] and were also SARS-CoV-2 antibody positive.
Further studies are needed to assess whether the presence of SARS-
CoV-2 antibodies, including neutralising antibodies, are protective
against re-infection and, if so, the duration of protection. Questions
also remain as to whether antibody concentrations provide a useful
measure of protection in infected individuals [17].
Interestingly, SARS-CoV-2 antibody levels were similar among
symptomatic and asymptomatic residents and staff across the care
homes [13]. The high fatality rates among residents across the six
care homes, particularly affecting those who had been symptomatic
and SARS-CoV-2 RT-PCR positive, indicates that the cohort described
here is more representative of milder illness and depleted of individ-
uals who suffered the most severe outcomes of infection [3]. We also
found that 90% of seropositive staff and residents had neutralising
antibody responses, with no significant differences in neutralising
antibody levels between by age, sex, symptom status, or staff/resi-
dent status. There was a trend towards increasing neutralising anti-
body titres with increasing age (Fig. 4c) but this was not statistically
significant. These findings of such robust antibody responses in sur-
viving care home residents, especially when compared to younger,
healthier staff members with similar exposure to SARS-CoV-2, are
novel and may play an important part in future recommendations for
infection control practices and vaccination against SARS-CoV-2.
Several key questions relating to this novel pandemic remain to
be answered and are particularly relevant to this highly vulnerable
population and setting. In particular, it is not known whether SARS-
CoV-2 antibodies are protective against re-infection [17]. We identi-
fied a small number of residents who were still RT-PCR positive up to
five weeks later; all of those tested had detectable antibodies, includ-
ing neutralising antibodies at the time of the persistent virus detec-
tion [18]. The RT-PCR Ct values were consistent with non-live virus in
all residents and staff members who were RT-PCR positive on nasal
swab at follow-up. The prolonged nasal swab RT-PCR positivity in a
proportion of residents and staff is consistent with a recent large
healthcare worker study where up to a quarter were still RT-PCR pos-
itive up to six weeks later, highlighting yet another limitation of our
understanding of the kinetics of viral replication and immune
responses COVID-19 [19,20]. This well-characterised cohort will be
followed with routine care home screening, [21] providing key
insights into the potential for reinfection in seropositive individuals.
Subsequent serology follow-up is planned for this cohort to explore
the longevity of serological responses.
The strengths of our investigations include the extensive and
robust epidemiological, virological and serological testing of resi-
dents and staff across six London care homes experiencing large out-
breaks of COVID-19, the broad age ranges involved, the daily follow-
up after initial testing and the high uptake for retesting five weeks
later. The data collected have provided a wealth of information on
SARS-CoV-2 infection, transmission and antibody responses in a
high-risk care setting involving a very vulnerable cohort. A limitation
is that the care homes were already in the middle of the outbreak.
Consequently, some residents had already developed COVID-19 and
some had died of their infection. Another limitation was that we did
not obtain blood samples for antibody testing at the first visit, which
could have provided additional useful information on antibody kinet-
ics in a large cohort of elderly residents and younger staff members.The lower nasal swab positivity during the initial investigations com-
pared to the antibody results five weeks later reflects the limited sen-
sitivity of the test, the quality of sampling, the stage of infection at
the time of testing and the gene targets used by different RT-PCR
assays [22]. Some of these limitations could potentially have been
mitigated by repeated swabbing at different time points. Finally, a
quarter of the residents and staff in the initial investigations were not
included in the follow-up, either because it was not possible to get
informed consent from the residents or their next of kin, or because
the staff were not working at the care home when follow-up investi-
gations were performed.
In conclusion, almost all residents and staff with confirmed SARS-
CoV-2 infection had detectable antibodies five weeks later, irrespec-
tive of whether they were ever symptomatic or remained asymptom-
atic throughout the outbreak. Additionally, a high proportion of those
who were symptomatic but SARS-CoV-2 RT-PCR negative were also
seropositive. SARS-CoV-2 antibody levels were not associated with
age, sex, PCR positivity, symptom status or resident/staff status. Our
findings demonstrate that older and vulnerable residents are able to
mount a robust antibody response to SARS-CoV-2 that is similar to
younger healthy staff members. This study highlights the value of
serological analysis in addition to RT-PCR screening to understand
SARS-CoV-2 exposure in this high-risk population, which is vital for
informing winter-planning and vaccine strategies. Further studies
are needed to determine whether SARS-CoV-2 antibodies protect
against re-infection and, if so, the duration of protection.
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